Shares of Eli Lilly LLY moved lower by 2.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 26.00% year over year to $1.89, which beat the estimate of $1.56.
Revenue of $5,499,000,000 declined by 2.45% year over year, which missed the estimate of $5,760,000,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $7.20 and $7.40.
The upcoming fiscal year's revenue expected to be between $23,700,000,000 and $24,200,000,000.
How To Listen To The Conference Call
Date: Jul 30, 2020
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/9cyavje9
Recent Stock Performance
Company's 52-week high was at $170.75
Company's 52-week low was at $101.36
Price action over last quarter: down 0.19%
Company Description
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.